Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(ribociclib)
241 results
  • Targeted therapy for breast cancer in older patients. [Review]
  • JGJ Geriatr Oncol 2019 Jun 03
  • Pondé N, Wildiers H, … Lago LD
  • Older patients are one of the most relevant sub-groups of patients with breast cancer and will only gain in importance as demographic transition unfolds. Their management, in both the early and advan…
  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. [Journal Article]
  • NEJMN Engl J Med 2019 Jun 04
  • Im SA, Lu YS, … Tripathy D
  • CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
  • The Role of CDK4/6 Inhibitors in Breast Cancer. [Review]
  • CTCurr Treat Options Oncol 2019 May 18; 20(6):52
  • Murphy CG
  • Oral inhibitors of CDK4/6 have been shown to increase response rates and prolong disease control when combined with endocrine therapy in hormone-responsive (HR+) HER2-negative advanced breast cancer.…
New Search Next